A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Inclusion criteria

• Are Overtly healthy males or nonpregnant females of childbearing or non-childbearing potential as determined through medical evaluation.
• Agree not to donate blood or plasma until after the end of their participation in the study
• Have a body mass index (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²)

Exclusion criteria

• Are females who are pregnant or lactating.
• Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
• Have a history or presence of psychiatric disorders
• Show evidence of human immunodeficiency virus infection.
• Show evidence of hepatitis C and/or hepatitis B
• Medical history of allergic reaction to humanized monoclonal antibodies
• Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
• Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes or are unable to abide by CRU smoking restrictions